'Lots of flaws': Bharat Biotech slams Covaxin-Covishield antibody study

Mini

Bharat Biotech has lashed out at a study on the comparative efficacy of Covishield and Covaxin. It says the study is not peer reviewed, among other things. Meanwhile, the fact that Bharat has not yet released its phase three trials data keeps coming up.

'Lots of flaws': Bharat Biotech slams Covaxin-Covishield antibody study

Market Movers

CompanyPriceChange%Gain
Maruti Suzuki7,432.70 167.30 2.30
Titan Company1,782.55 25.55 1.45
Bajaj Finserv12,282.25 150.60 1.24
ONGC123.35 1.30 1.07
M&M781.95 6.75 0.87
CompanyPriceChange%Gain
Maruti Suzuki7,432.95 169.20 2.33
Titan Company1,783.00 26.20 1.49
Bajaj Finserv12,280.80 147.75 1.22
M&M781.90 6.50 0.84
UltraTechCement6,903.70 47.20 0.69
CompanyPriceChange%Gain
Maruti Suzuki7,432.70 167.30
Titan Company1,782.55 25.55
Bajaj Finserv12,282.25 150.60
ONGC123.35 1.30
M&M781.95 6.75
CompanyPriceChange%Gain
Maruti Suzuki7,432.95 169.20
Titan Company1,783.00 26.20
Bajaj Finserv12,280.80 147.75
M&M781.90 6.50
UltraTechCement6,903.70 47.20

Currency

CompanyPriceChng%Chng
Dollar-Rupee74.2700-0.0950-0.13
Euro-Rupee88.5440-0.1910-0.22
Pound-Rupee103.5270-0.1410-0.14
Rupee-100 Yen0.6700-0.0020-0.29